Live Breaking News & Updates on Corticosteroids Prior

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® in adult patients with relapsed or refractory large B-cell lymphoma . Results …
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients ....

United States , Santa Monica , Foster City , Jacquie Ross , Olalekano Oluwole , Nathan Kaiser , Frank Neumann , Gilead Sciences , Vanderbilt University Medical Center , Drug Administration , Kite Global Head Of Clinical Development , Gilead Sciences Inc , International Blood Marrow Transplant Research , Exchange Commission , Gilead Company , Gilead Public Affairs , Gilead Company Nasdaq , Corticosteroids Prior , Yescarta Infusion Has , Risk Profile Based , Response Rates Observed , New Analysis Remain Consistent , Pivotal Cohorts , Cellular Therapy Meetings , American Society , Cellular Therapy ,